<DOC>
	<DOCNO>NCT02273765</DOCNO>
	<brief_summary>Phase III trial evaluate raltegravir alternative efavirenz antiretroviral treatment HIV-infected patient tuberculosis .</brief_summary>
	<brief_title>Raltegravir Versus Efavirenz Naive HIV-1-infected Patients Receiving Rifampin Active Tuberculosis</brief_title>
	<detailed_description>Phase III multicenter , international , open-label , randomized trial evaluate non-inferiority raltegravir dose 400mg BID compare efavirenz 600mg QD , association tenofovir disoproxil fumarate lamivudine ART-naïve HIV-1 infect patient active TB disease receive rifampin-based TB treatment initiate &lt; 8 week inclusion . Patients randomize 2 arm : raltegravir ( RAL ) 400 mg bid arm efavirenz ( EFV ) 600 mg qd arm , combination tenofovir disoproxil fumarate ( TDF ) lamivudine ( 3TC ) follow 48 week entry trial ( ART initiation ) .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Signed informed consent form Aged 18 year Confirmed HIV1 infection document time prior trial entry per national HIV testing procedure ART naïve For woman childbearing potential i.e . woman childbearing age menopausal , permanently sterilize ( e.g . tubal occlusion , hysterectomy , bilateral salpingectomy ) refrain sexual activity : negative urinary test pregnancy acceptance use contraceptive method Confirmed probable active TB disease location , except neurological ( meningitis encephalitis ) , accord follow criterion base WHO update definition : Bacteriologically confirm pulmonary TB ( PTB ) extrapulmonary TB ( EPTB ) , e.g . TB biological specimen positive smear microscopy , culture nucleic acid amplification test ( Xpert MTB/RIF ) . Clinically diagnose PTB EPTB typical histological evidence TB ( caseous granulomatous ) biopsy specimen positive urinary LAM test OR significant improvement TB treatment Ongoing standard rifampincontaining TB treatment ≤8 week inclusion For French patient , affiliation Social Security program HIV2 coinfection Impaired hepatic function ( icterus ALT ( SGPT ) &gt; 5ULN ) Hemoglobin &lt; 6.5 g/dl Creatinine clearance &lt; 60ml/min ( assess Cockroft Gault formula ) Mycobacterium tuberculosis strain resistant rifampin ( current past history ) . Neurological TB ( meningitis encephalitis ) Severe associate disease require specific treatment ( include specific AIDS defining illness TB , severe sepsis ) Any condition might , investigator 's opinion , compromise safety treatment and/or patient 's adherence trial procedure include severe TBrelated clinical condition Concomitant treatment include phenytoin phenobarbital ( compound interact UGT1A1 ) For HCV coinfected patient , need start specific treatment hepatitis trial duration For woman childbearing potential : Pregnancy breastfeed Refusal use contraceptive method Any history ARV intake prevention mother child transmission HIV ( pMTCT ) Subjects participate another clinical trial evaluate therapy include exclusion period still force screen phase Person guardianship , deprive freedom judicial administrative decision</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>